Old Web
English
Sign In
Acemap
>
authorDetail
>
James DRozario
James DRozario
Australian National University
Internal medicine
Rituximab
Chronic lymphocytic leukemia
Oncology
Medicine
2
Papers
24
Citations
0.00
KQI
Citation Trend
Filter By
Interval:
1900~2024
1900
2024
Author
Papers (2)
Sort By
Default
Most Recent
Most Early
Most Citation
No data
Journal
Conference
Others
Five-Year Analysis of Murano Study Demonstrates Enduring Undetectable Minimal Residual Disease (uMRD) in a Subset of Relapsed/Refractory Chronic Lymphocytic Leukemia (R/R CLL) Patients (Pts) Following Fixed-Duration Venetoclax-Rituximab (VenR) Therapy (Tx)
2020
Blood
Arnon P. Kater
Thomas J. Kipps
Barbara Eichhorst
Peter Hillmen
James DRozario
Carolyn Owen
Sarit Assouline
Nicole Lamanna
T. Robak
Javier de la Serna
Ulrich Jaeger
Guillaume Cartron
Marco Montillo
Clemens Mellink
Brenda Chyla
Cameron Wilson
Jenny Wu
Yanwen Jiang
Marcus Lefebure
Michelle Boyer
John F. Seymour
Show All
Source
Cite
Save
Citations (19)
Efficacy of Subsequent Novel Targeted Therapies, Including Repeated Venetoclax-Rituximab (VenR), in Patients (Pts) with Relapsed/Refractory Chronic Lymphocytic Leukemia (R/R CLL) Previously Treated with Fixed-Duration Venr in the Murano Study
2020
Blood
Rosemary Harrup
Carolyn Owen
James DRozario
Tadeusz Robak
Arnon P. Kater
Marco Montillo
Javier de la Serna
Marek Trneny
Su Young Kim
Edward Bataillard
Marcus Lefebure
Michelle Boyer
John F. Seymour
Show All
Source
Cite
Save
Citations (5)
1